Drug Information

Drug General Information
Drug ID
D0PU9C
Former ID
DNCL001983
Drug Name
TTP-448
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2 [550058]
Company
TransTech Pharma
Target and Pathway
Target(s) Advanced glycosylation end product-specific receptor Target Info Modulator [533109]
Pathway Interaction Database amb2 Integrin signaling
Reactome RIP-mediated NFkB activation via ZBP1
DEx/H-box helicases activate type I IFN and inflammatory cytokines production
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Advanced glycosylation endproduct receptor signaling
TRAF6 mediated NF-kB activation
WikiPathways NRF2 pathway
Nuclear Receptors Meta-Pathway
Cytosolic sensors of pathogen-associated DNA
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
AGE/RAGE pathway
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
Advanced glycosylation endproduct receptor signaling
References
Ref 550058Biopharmaceutical Research Companies are Developing Nearly 100 Medicines for Alzheimer's Disease and Other Dementias. Pharmaceutical Research and Manufacturers of America report. 2012.
Ref 533109Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.